Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 451 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ritonavir (rtv) Clear all
Approved For Marketing No phase listed Expanded access

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

NCT00097799
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Timeline
Started 2004
U.S. locations
115
States / cities
Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

NCT04960202
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Ritonavir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
73
States / cities
Pelham, Alabama • Mesa, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

NCT00016601
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz, Nevirapine, Medroxyprogesterone acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

NCT01185873
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 9:59 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

NCT00002241
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 9:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

NCT00259727
View directory record Official record
Conditions
Diabetes, HIV Infections, Insulin Resistance
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 72 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 4 Interventional

A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects

NCT01045369
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra and Intelence Tablets
Drug
Lead sponsor
Therapeutic Concepts
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

NCT00697892
View directory record Official record
Conditions
HIV Infections, Malaria
Interventions
lopinavir/ritonavir, efavirenz, artemether/lumefantrine
Drug
Lead sponsor
Fran Aweeka
Other
Eligibility
21 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 14, 2026, 9:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

NCT00743470
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
lopinavir/ritonavir, rifabutin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Not applicable Interventional

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

NCT00000859
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
32
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 4 Interventional Results available

Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

NCT01010399
View directory record Official record
Conditions
Hypertriglyceridemia, HIV Infection
Interventions
Lovaza, fosamprenavir/ritonavir
Dietary Supplement · Drug
Lead sponsor
Felizarta, Franco, M.D.
Individual
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bakersfield, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

NCT00046033
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Amprenavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Miami, Florida • Honolulu, Hawaii • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

NCT00357604
View directory record Official record
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

NCT05064800
View directory record Official record
Conditions
Healthy Participants
Interventions
Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

NCT00135343
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanvir/ritonavir + efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
15
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlantis, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Not applicable Interventional

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

NCT00000914
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

NCT01571414
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824, Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r), Rifampin (RIF)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 14, 2026, 9:59 PM EDT
Not listed No phase listed Observational

BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects

NCT00388492
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Bellos, Nicholaos C., M.D.
Individual
Eligibility
18 Years and older
Enrollment
45 participants
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2007 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

NCT00001083
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
58
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

NCT00949234
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
tenofovir + emtricitabine, lopinavir/ritonavir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

NCT00936793
View directory record Official record
Conditions
HIV, Asthma
Interventions
Darunavir, Ritonavir, Beclomethasone Dipropionate HFA
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 9:59 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

NCT01602822
View directory record Official record
Conditions
HIV
Interventions
Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Drug
Lead sponsor
Kenneth H. Mayer, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

NCT00086359
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 4 Interventional

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

NCT00055120
View directory record Official record
Conditions
HIV Infections, AIDS-Related Opportunistic Infections
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
43
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 14, 2026, 9:59 PM EDT